{ "resourceType" : "Evidence", "id" : "367940", "meta" : { "versionId" : "26", "lastUpdated" : "2025-08-18T13:22:42.074Z", "profile" : ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"] }, "language" : "en", "text" : { "status" : "extensions", "div" : "

Generated Narrative: Evidence 367940

version: 26; Last updated: 2025-08-18 13:22:42+0000; Language: en

Profile: NonComparativeEvidence

ArtifactPublicationStatus: Active

url: https://fevir.net/resources/Evidence/367940

identifier: FEvIR Object Identifier/367940, FEvIR Linking Identifier/NCT03640312-otherOutcomeMeasure-6--OG001

name: NCT03640312_otherOutcomeMeasure_6_OG001

title: Mean Change in Serum Creatinine at 12 weeks for Candesartan in NCT03640312

citeAs:

Mean Change in Serum Creatinine at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367940. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367940. Computable resource at: https://fevir.net/resources/Evidence/367940#json.

\n

status: Active

author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:

publisher: Computable Publishing LLC

contact: support@computablepublishing.com

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

\n

description:

This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.

\n

variableDefinition

description:

Candesartan

\n

note: ,

Outcome Measure Population Description: Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.

\n

Outcome Measure Denominator Units: Participants

\n

variableRole: Population

observed: Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks. (Identifier: ClinicalTrials.gov Outcome Measurement Group Id/OG001)

variableDefinition

variableRole: Outcome

observed: Mean Change in Serum Creatinine at 12 weeks - (NCT03640312)

statistic

statisticType: mean

quantity: -0.04 mg/dL

SampleSizes

-KnownDataCount
*30

AttributeEstimates

-TypeQuantity
*Standard Deviation0.11 mg/dL
" }, "extension" : [{ "url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status", "valueCodeableConcept" : { "coding" : [{ "system" : "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type", "code" : "active", "display" : "Active" }] } }], "url" : "https://fevir.net/resources/Evidence/367940", "identifier" : [{ "type" : { "coding" : [{ "system" : "http://terminology.hl7.org/CodeSystem/v2-0203", "code" : "ACSN", "display" : "Accession ID" }], "text" : "FEvIR Object Identifier" }, "system" : "https://fevir.net/FOI", "value" : "367940", "assigner" : { "display" : "Computable Publishing LLC" } }, { "type" : { "text" : "FEvIR Linking Identifier" }, "system" : "https://fevir.net/FLI", "value" : "NCT03640312-otherOutcomeMeasure-6--OG001", "assigner" : { "display" : "Computable Publishing LLC" } }], "name" : "NCT03640312_otherOutcomeMeasure_6_OG001", "title" : "Mean Change in Serum Creatinine at 12 weeks for Candesartan in NCT03640312", "citeAs" : "Mean Change in Serum Creatinine at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367940. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367940. Computable resource at: https://fevir.net/resources/Evidence/367940#json.", "status" : "active", "author" : [{ "name" : "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter" }], "publisher" : "Computable Publishing LLC", "contact" : [{ "telecom" : [{ "system" : "email", "value" : "support@computablepublishing.com" }] }], "copyright" : "https://creativecommons.org/licenses/by-nc-sa/4.0/", "description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.", "variableDefinition" : [{ "description" : "Candesartan", "note" : [{ "text" : "Outcome Measure Population Description: Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol." }, { "text" : "Outcome Measure Denominator Units: Participants" }], "variableRole" : "population", "observed" : { "identifier" : { "type" : { "text" : "ClinicalTrials.gov Outcome Measurement Group Id" }, "value" : "OG001" }, "display" : "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks." } }, { "variableRole" : "outcome", "observed" : { "reference" : "EvidenceVariable/367902", "type" : "EvidenceVariable", "identifier" : { "type" : { "text" : "FEvIR Linking Identifier" }, "system" : "https://fevir.net/FLI", "value" : "NCT03640312-otherOutcome-6", "assigner" : { "display" : "Computable Publishing LLC" } }, "display" : "Mean Change in Serum Creatinine at 12 weeks - (NCT03640312)" } }], "statistic" : [{ "statisticType" : { "coding" : [{ "system" : "https://fevir.net/sevco", "code" : "STATO:0000573", "display" : "mean" }] }, "quantity" : { "value" : -0.04, "unit" : "mg/dL" }, "sampleSize" : { "knownDataCount" : 30 }, "attributeEstimate" : [{ "type" : { "text" : "Standard Deviation" }, "quantity" : { "value" : 0.11, "unit" : "mg/dL" } }] }] }